Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post Marketing Surveillance Study to Monitor the Reactogenicity and Safety of Vaxem™Hib When Administered According to the Prescribing Information in Korea

NCT01404962 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01404962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01404962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post Marketing Surveillance Study to Monitor the Reactogenicity and Safety of Vaxem™Hib When Administered According to the Prescribing Information in Korea
Lead sponsor
Novartis Vaccines
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2011
Completion date
July 31, 2012
Enrollment
764 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilus influenzae type b infection